ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1047

Signaling at Adenosine A2A Receptor (A2aR) in Osteoblasts; Crosstalk with Wnt/ β-Catenin Signaling Pathway

Soheila Borhani1, Carmen Corciulo2, Ane Larrañaga Vera3 and Bruce N. Cronstein4, 1Medicine, Division of Translational Medicine, New York University School of Medicine, New York, NY, 2Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 3Medicine, New York University School of Medicine, New York, NY, 4Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: adenosine receptors and osteoblasts, WNT Signaling

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Osteoarthritis and Joint Biology – Basic Science Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The Wnt/β-catenin signaling pathway plays a key role in regulating bone formation and maintaining bone hemostasis. Wnt activates a pathway that leads to stabilization of β-catenin and its translocation to the nucleus. Osteoblast differentiation and proliferation are also regulated by adenosine receptors, among other signals. We recently reported that A2aR signaling promotes Wnt/β-catenin signaling in fibroblasts via activation of Akt and p38MAPK. In the present study we sought to determine whether there is a similar interaction between these pathways in osteoblasts.

Methods: We studied murine osteoblast cell line (MC3T3-E1) and primary osteoblasts derived from bone marrow-derived mesenchymal stem cells of mice. The cells were treated with CGS21680, a selective A2aR agonist, at doses ranging from 0 to 10µM, and for varying incubation periods up to 240 minutes. Levels of phosphorylated β-catenin at Ser552 (p-Ser552), a β-catenin isoform with enhanced transcriptional activity, were measured by Western Blot assays before and after A2aR activation. We also analyzed nuclear translocation of p-Ser552 β-catenin in the osteoblastoid cell line and primary cell cultures using immunofluorescence (IF) staining. Cellular levels of activated AKT were measured by immunoblotting assays before and following administration of CGS21680.

Results: We observed a significant increase in p-Ser552 β-catenin levels in the osteoblastoid cells treated with 1 µM CGS21680 compared to the control, starting at 15 minutes following A2aR activation (253±122%, p<0.05, n=5). Western blot analysis showed a significant increase in nuclear translocation of p-Ser552 β-catenin at 15 minutes after treatment with A2aR agonist in MC3T3-E1 cells (153±37%, p<0.05, n=4), and primary osteoblasts (148±31%, p<0.05, n=4). Similarly, immunofluorescence revealed approximately a 40% increase in nuclear accumulation of p-Ser552 β-catenin in CGS21680-treated MC3T3-E1 cells as well as in primary osteoblasts. We also found a significant increase in the levels of phosphorylated AKT at Ser473 among osteoblastoid cells following A2aR stimulation (203±47%, p<0.05, n=4).

Conclusion: These findings demonstrate cross-talk between A2aR and Wnt/β-catenin signaling pathways in osteoblasts. Moreover, our results suggest that A2aR activation can bypass blockade of Wnt ligands at the cell surface and thereby maintain bone homeostasis.


Disclosure: S. Borhani, None; C. Corciulo, Regenosine, 1,Intellectual property, 9; A. Larrañaga Vera, None; B. N. Cronstein, Cantic Biopharma, Regenosine, 1,NIH Arthitis foundation, Astrazeneca, 2,Horizon Pharmaceuticals, Regenosine, 5,Patent issued and pending, 9.

To cite this abstract in AMA style:

Borhani S, Corciulo C, Larrañaga Vera A, Cronstein BN. Signaling at Adenosine A2A Receptor (A2aR) in Osteoblasts; Crosstalk with Wnt/ β-Catenin Signaling Pathway [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/signaling-at-adenosine-a2a-receptor-a2ar-in-osteoblasts-crosstalk-with-wnt-%ce%b2-catenin-signaling-pathway/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/signaling-at-adenosine-a2a-receptor-a2ar-in-osteoblasts-crosstalk-with-wnt-%ce%b2-catenin-signaling-pathway/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology